IGF-1 LR3 Dosage, Protocol, and Reconstitution Guide
IGF-1 LR3
IGF-1 LR3 (Long R3 IGF-1) is a modified analog of insulin-like growth factor 1 (IGF-1) designed to have reduced binding to IGF-binding proteins and prolonged biological activity compared with native IGF-1. It is primarily a research compound, and human clinical evidence for the LR3 analog itself is extremely limited.
How IGF-1 LR3 Works
IGF-1 Receptor Activation → Growth + Metabolic Signaling → Protein Synthesis + Glucose Utilization
IGF-1 LR3 is designed to activate the IGF-1 receptor while interacting less strongly with IGF-binding proteins than native IGF-1. IGF-1 receptor signaling influences cellular growth, protein metabolism, and glucose utilization. However, many clinical effects associated with IGF-1 come from studies of native or recombinant human IGF-1 rather than IGF-1 LR3 itself.
IGF-1 LR3 is a modified analog of IGF-1.
It acts downstream of the GH pathway rather than stimulating growth hormone release.
Most human clinical evidence involves recombinant human IGF-1, not the LR3 analog.
IGF signaling can significantly influence glucose metabolism, making glucose-related effects an important safety consideration.
IGF-1 LR3 Research Protocol
1 mg vial + 2.0 mL BAC Water → 1 unit = 5 mcg → Long-Acting IGF-1 Support
Standard Setup
Vial
1 mg
Water
2.0 mL bacteriostatic water
Concentration
0.5 mg/mL
Conversion
1 unit = 5 mcg
Weeks 1–2
Start Phase
Dose20 mcg
Units4 units
Volume0.04 mL
Weeks 3–4
Build Phase
Dose30 mcg
Units6 units
Volume0.06 mL
Weeks 5–8
Peak Phase
Dose40 mcg
Units8 units
Volume0.08 mL
Weeks 9–12
Advanced Extension
Dose50 mcg
Units10 units
Volume0.10 mL
Protocol Details
FrequencyOnce daily
TimingPost-workout or earlier in the day
Cycle Length4–8 weeks
Advanced ExtensionUp to 12 weeks
Research context:
The dose ranges shown above reflect commonly discussed research/community practices rather than a clinically validated IGF-1 LR3 titration schedule. Human trials have not established a standard LR3 dose, progression, treatment duration, or therapeutic range.
The dose ranges shown above reflect commonly discussed research/community practices rather than a clinically validated IGF-1 LR3 titration schedule. Human trials have not established a standard LR3 dose, progression, treatment duration, or therapeutic range.
How to Use IGF-1 LR3 (Timing & Injection)
Use StyleTraining-focused anabolic support
Research TimingPost-workout or earlier in the day
Research FrequencyOnce daily
RouteSubcutaneous injection is most common
Clinical LR3 Route
No standardized human regimen established
Injection Notes
Subcutaneous injection is most common
Often used post-workout or earlier in the day
Abdomen, thigh, or upper arm are common sites
Rotate injection sites consistently
Timing Notes
Post-workout timing is frequently discussed in performance communities but has not been established as superior in human IGF-1 LR3 trials.
There is no established evidence that IGF-1 LR3 must be administered immediately after training.
Because IGF signaling can affect glucose metabolism, glucose-related symptoms are an important consideration.
Reconstitution & Dosing (1 mg Vial)
Vial1 mg
Water2.0 mL
Concentration500 mcg/mL
Conversion1 unit = 5 mcg
Dose Reference
4 units = 20 mcg
6 units = 30 mcg
8 units = 40 mcg
10 units = 50 mcg
20 units = 100 mcg
Reconstitution Steps
Draw 2.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C
Long-term storage: freezing at −20°C is commonly preferred
Keep the vial sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Avoid leaving lyophilized peptide at room temperature for extended periods
Do not repeatedly freeze and thaw the same vial
Estimated Unmixed Shelf Life
Refrigerated (2–8°C): commonly ~12–24 months when sealed and dry
Frozen (−20°C): commonly up to ~2–3 years when stored properly
Actual stability depends on supplier quality, handling, and storage conditions
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~30 days
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Storage note:
Stability depends on formulation, purity, handling, and storage conditions. Follow product-specific laboratory, manufacturer, or pharmacy stability information when available rather than assuming a universal shelf life for lyophilized or reconstituted IGF-1 LR3.
Stability depends on formulation, purity, handling, and storage conditions. Follow product-specific laboratory, manufacturer, or pharmacy stability information when available rather than assuming a universal shelf life for lyophilized or reconstituted IGF-1 LR3.
Research Cycle Length & Time Between Cycles
Research Exposure → Monitor Response → Reassess → Continue or Stop
Standard Research Cycle Structure
Cycle Length4–8 weeks
Advanced ExtensionUp to 12 weeks
Established Cycle Length
None established for IGF-1 LR3
Primary PhaseTraining-focused recovery and nutrient partitioning support
GoalLean mass support + recovery + training output
Research Time Between Cycles
Break4–8 weeks
Established Off-Cycle
None established
Possible growth-pathway signaling to reset
Discussed to help reduce diminishing returns from continuous exposure
Gives time to assess recovery, fullness, glucose response, and training changes
Why cycle?
IGF-1 LR3 is usually discussed kept to shorter, intentional cycles because it is more potent than many beginner peptides and works directly on growth-related pathways. Cycling helps keep the protocol more controlled and easier to evaluate.
IGF-1 LR3 is usually discussed kept to shorter, intentional cycles because it is more potent than many beginner peptides and works directly on growth-related pathways. Cycling helps keep the protocol more controlled and easier to evaluate.
When to Stop or Pause Early
Low-blood-sugar-like symptoms occur
Water retention becomes uncomfortable
Headaches or fatigue increase
Training recovery or body composition changes plateau
You are continuing without a clear training or recovery goal
Important distinction:
Published human research does not establish a required IGF-1 LR3 cycle length, mandatory break, or receptor-reset period. Common 4–8 week cycles and similar off-cycle recommendations come from community practice rather than validated clinical protocols.
Published human research does not establish a required IGF-1 LR3 cycle length, mandatory break, or receptor-reset period. Common 4–8 week cycles and similar off-cycle recommendations come from community practice rather than validated clinical protocols.
Human Clinical Research: What We Actually Know
IGF-1 LR3
Human Evidence
Very limited / not clinically established
Approved Use
None
Common IGF-1 LR3 dosing, cycling, bodybuilding, and recovery protocols are not established through human clinical trials.
Related Human IGF-1 Research
Recombinant human IGF-1 has been studied clinically, but it is not the same molecule as IGF-1 LR3.
Human studies show that rhIGF-1 can increase glucose utilization and influence insulin secretion.
Human research has also demonstrated effects on protein metabolism and body composition in specific clinical populations.
These findings help explain the biology of the IGF-1 pathway but should not be treated as direct clinical evidence for IGF-1 LR3.
Important distinction:
IGF-1 LR3 and recombinant human IGF-1 are related but different molecules. Human rhIGF-1 research can help explain IGF-1 receptor biology and potential risks, but it does not validate the dosing, effectiveness, or safety of IGF-1 LR3 protocols used outside clinical research.
IGF-1 LR3 and recombinant human IGF-1 are related but different molecules. Human rhIGF-1 research can help explain IGF-1 receptor biology and potential risks, but it does not validate the dosing, effectiveness, or safety of IGF-1 LR3 protocols used outside clinical research.
Monitoring During Use
Blood glucose and symptoms consistent with hypoglycemia
Insulin and glucose regulation when clinically appropriate
Fluid retention or swelling
Headache, dizziness, sweating, shakiness, or unusual fatigue
Unexpected tissue or soft-tissue changes during prolonged exposure
Why glucose matters:
Human studies of recombinant IGF-1 demonstrate significant effects on glucose disposal and insulin secretion. Although these studies did not use IGF-1 LR3, they provide important safety context for compounds acting through the IGF-1 pathway.
Human studies of recombinant IGF-1 demonstrate significant effects on glucose disposal and insulin secretion. Although these studies did not use IGF-1 LR3, they provide important safety context for compounds acting through the IGF-1 pathway.
Benefits
Activates the IGF-1 receptor pathway
IGF-1 signaling is involved in cellular growth and protein metabolism
Related human IGF-1 research demonstrates effects on protein synthesis and glucose metabolism
Potential effects on muscle growth, recovery, and body composition are major reasons LR3 is discussed in performance research
These performance outcomes have not been established through controlled human IGF-1 LR3 trials
Potential Side Effects
Injection site irritation
Possible headache
Water retention
Low blood sugar symptoms in sensitive users
Possible fatigue or dizziness if glucose response is affected
Combination & Stacking Considerations
IGF-1 Receptor Signaling → Consider Pathway Overlap → Monitor Metabolic Effects
Commonly Discussed Combinations
IGF-1 LR3 + BPC-157: Discussed for recovery-focused research with less direct overlap in the GH/IGF-1 pathway.
IGF-1 LR3 + Ipamorelin: Adds GH secretagogue activity upstream of IGF-1 and may increase overall GH/IGF-axis signaling.
IGF-1 LR3 + CJC-1295: Adds GHRH-driven GH stimulation upstream of IGF-1, creating additional growth-pathway overlap.
Higher-Overlap Combinations
Combining IGF-1 LR3 with both a GHRH analog and a GHRP can layer multiple points of the GH/IGF-1 axis.
More pathway activation does not automatically mean better results and may increase metabolic or growth-related concerns.
Human clinical trials have not established the safety or effectiveness of these IGF-1 LR3 combinations.
What to Watch
Glucose changes or symptoms consistent with low blood sugar
Fluid retention or swelling
Excessive GH/IGF-1 pathway overlap
Adding multiple growth-pathway compounds without a clear research rationale
Important context
IGF-1 LR3 acts directly through the IGF-1 receptor pathway, while compounds such as CJC-1295 and Ipamorelin act upstream by stimulating growth hormone release. Combining them therefore layers different parts of the same GH/IGF-1 axis. These combinations are discussed in research and performance communities, but they are not clinically validated IGF-1 LR3 treatment protocols.
IGF-1 LR3 acts directly through the IGF-1 receptor pathway, while compounds such as CJC-1295 and Ipamorelin act upstream by stimulating growth hormone release. Combining them therefore layers different parts of the same GH/IGF-1 axis. These combinations are discussed in research and performance communities, but they are not clinically validated IGF-1 LR3 treatment protocols.
Important Notes
IGF-1 LR3 is a modified IGF-1 analog, not a growth hormone secretagogue.
Human clinical evidence for IGF-1 LR3 itself is extremely limited.
Human studies of recombinant IGF-1 should not be presented as direct evidence for IGF-1 LR3.
Common dosing, timing, cycling, and stacking protocols are largely community-derived rather than clinically established.
IGF-1 pathway activity can influence glucose metabolism, making glucose-related effects an important safety consideration.
Important Disclaimer
IGF-1 LR3 is not FDA-approved for human therapeutic use. Published human research involving recombinant human IGF-1 does not establish the safety, effectiveness, dosing, or long-term risks of IGF-1 LR3. This content is for educational purposes only.
Important Disclaimer
IGF-1 LR3 is not FDA-approved and is intended for research purposes only.
Research & References
Primary Research
- King R, Wells JR, Krieg P, et al. Production and Characterization of Recombinant Insulin-Like Growth Factor-I (IGF-I) and Potent Analogues of IGF-I, with Gly or Arg Substituted for Glu3, Following Their Expression in Escherichia coli as Fusion Proteins. Journal of Molecular Endocrinology. 1992.
- Tomas FM, Knowles SE, Chandler CS, Francis GL, Owens PC, Ballard FJ. Anabolic Effects of Insulin-Like Growth Factor-I (IGF-I) and an IGF-I Variant in Normal Female Rats. Journal of Endocrinology. 1993.
- Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 Insulin-Like Growth Factor-I (IGF-I) Infusion Stimulates Organ Growth but Reduces Plasma IGF-I, IGF-II and IGF Binding Protein Concentrations in the Guinea Pig. Journal of Endocrinology. 1995.
Research Note: The studies above establish Long R3 IGF-1's reduced binding to IGF-binding proteins and its resulting biological potency in preclinical models. Human clinical dosing data for IGF-1 LR3 are very limited; self-administration protocols described on this page are drawn from compounding-community practice rather than validated human trials.
Comments
Post a Comment